Sun.Nov 19, 2023

article thumbnail

ADCs as biological missiles for targeted therapies

Pharmaceutical Technology

ADCs continue to demonstrate efficacy across different tumor types, and their use is expected to expand across indications as more suitable target antigens are identified and new and better technologies emerge.

130
130
article thumbnail

5 Cancer Vaccines to Watch in 2024

BioSpace

BioSpace takes a deep dive into five investigational therapeutic cancer vaccines that have recently shown efficacy in difficult-to-treat indications.

Vaccine 128
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Lilly to invest $2.5bn for obesity, diabetes drug production

pharmaphorum

Lilly to invest $2.5bn for obesity, diabetes drug production Phil.

article thumbnail

The Next Generation of Weight Loss Drugs is Rapidly Approaching

BioSpace

Successful drugs from Novo Nordisk and Eli Lilly are just the beginning of what one analyst says could be “the largest therapeutic class of drugs that the biopharma industry has ever seen.

Drugs 118
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Risk of Bleeding Following NOAC Use in Patients With Acute Ischemic Stroke Treated With Alteplase

JAMA Internal Medicine

This Taiwanese cohort study evaluates the risk of bleeding and mortality after alteplase treatment for patients with acute ischemic stroke treated with non–vitamin K antagonist oral anticoagulants (NOACs) vs not treated with NOACs.

101
101
article thumbnail

With New Phase III Data in Hand, Servier Eyes FDA Filing for Glioma Candidate

BioSpace

Vorasidenib decreased tumor volume by a mean of 2.5% every six months, compared to growth of 13.9% for placebo over the same time span. The candidate is also being tested in a regimen with Keytruda.

92

More Trending

article thumbnail

Playing in the Hot Obesity Market, Carmot Braves Chilly IPO Waters

BioSpace

Armed with a pipeline of obesity and diabetes hopefuls, Carmot Therapeutics joins the small group of biotechs to attempt a Nasdaq debut this year.

article thumbnail

Underappreciated One-Size-FIts-All Health Inequity

JAMA Internal Medicine

This Viewpoint discusses why health priorities–tailored care, rather than the one-size-fits-all approach, is beneficial for marginalized individuals.

75
article thumbnail

Outclassed by Eliquis, Bayer Halts Atrial Fibrillation Study of Factor XIa In.

BioSpace

Bayer’s investigational factor XIa inhibitor asundexian was inferior to BMS' and Pfizer’s blockbuster blood thinner Eliquis (apixaban) in the Phase III OCEANIC-AF study.

75
article thumbnail

Which pharmaceutical companies have the most SPCs in Slovakia?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Slovakia. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating… The post Which pharmaceutical companies have the most SPCs in Slovakia? appeared first on DrugPatentWatch - Make Better Decisions.

59
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

NHS, Pharma Deal Doubles Annual Growth and Earmarks £400M for R&D

BioSpace

The new five-year deal will save the U.K.’s National Health Service an estimated £14 billion ($17.4 billion) and double the annual allowed growth in sales of branded medicines from 2% to 4% per year by 2027.

article thumbnail

New patent expiration for Collegium Pharm drug NUCYNTA ER

Drug Patent Watch

Annual Drug Patent Expirations for NUCYNTA+ER Nucynta Er is a drug marketed by Collegium Pharm Inc and is included in one NDA. It is available from one supplier. There are… The post New patent expiration for Collegium Pharm drug NUCYNTA ER appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59
article thumbnail

Is Your Serialization Program Complete and Sustainable?

Pharmaceutical Commerce

Webinar Date/Time: Thu, Dec 14, 2023 11:00 AM EST

52
article thumbnail

New patent expiration for Purdue Pharma drug HYSINGLA ER

Drug Patent Watch

Annual Drug Patent Expirations for HYSINGLA+ER Hysingla Er is a drug marketed by Purdue Pharma Lp and is included in one NDA. It is available from one supplier. There are… The post New patent expiration for Purdue Pharma drug HYSINGLA ER appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Repeatedly Malignant ST-Segment Elevation

JAMA Internal Medicine

This case report describes a patient in their early 50s who presented with epigastric pain and jaundice and had significantly decreased heart rate after admission.

40
article thumbnail

New patent expiration for Purdue Pharma drug OXYCONTIN

Drug Patent Watch

Annual Drug Patent Expirations for OXYCONTIN Oxycontin is a drug marketed by Purdue Pharma Lp and is included in one NDA. It is available from five suppliers. There are twenty-one… The post New patent expiration for Purdue Pharma drug OXYCONTIN appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59
article thumbnail

How Do Therapy Manufacturers Envision the Future of Hubs?

Pharmaceutical Commerce

CareMetx, a Hub services company that provides high-touch support to drive therapy initiation and adherence, conducted research involving over 100 participants, using both qualitative and quantitative methods. The primary aim was to understand how therapy manufacturers envision the future of Hubs.

article thumbnail

New patent expiration for Endo Pharms drug OPANA ER

Drug Patent Watch

Annual Drug Patent Expirations for OPANA+ER Opana Er is a drug marketed by Endo Pharms and is included in two NDAs. There are eleven patents protecting this drug and six… The post New patent expiration for Endo Pharms drug OPANA ER appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Data is Becoming a Differentiator for Hubs that Support Specialty Drugs

Pharmaceutical Commerce

In a recent study, CareMetx engaged with senior leadership at leading biopharmaceutical manufacturers, aiming to evaluate the optimal ways in which Hub data can enhance manufacturer support. These findings can serve as a valuable guide for manufacturers seeking insights on optimizing their utilization of Hub data.

article thumbnail

What Do Pharmaceutical Manufacturers Actually Want Most from a Hub?

Pharmaceutical Commerce

Among a variety of Hub vendors, what specific qualities distinguish differentiated support for drug manufacturers? To help answer this question, CareMetx conducted in-depth interviews and surveys with senior leadership at top manufacturers.